SLC5A2 and Abnormal renal physiology: Clinical trials of similar design on other SGLT2 inhibitors, e.g., canagliflozin and dapagliflozin, have consistently shown that these drugs prevent heart failure and renal dysfunction in patients with diabetes, e.g., [8,9].